The global vulvovaginal candidiasis treatment market is currently valued at US$ 1035 million in 2023, with a CAGR of 4.5% expected. Because of technological advancements in the healthcare sector, the market is expected to reach US$1607 million by 2033.
According to FMI, a market research and competitive intelligence provider, the vulvovaginal candidiasis industry grew at a 4.3% CAGR between 2018 and 2022.
Vaginal yeast infection is a common fungal infection and is called candidal vaginitis or candidal vulvovaginitis Symptoms of vaginal yeast infection include itching, burning sensation or pain during urination or sexual intercourse, swelling, rashes, and redness.
Candida albicans is the most common cause of human fungal infections. The most common cause of fungal urinary tract infections is Candida species (UTIs). Candida UTIs can occur in the lower urinary tract or, in some cases, ascend to the kidneys. In many cases, the antifungal drug fluconazole can be used. Individuals' VVC prevalence has increased due to an increase in diabetes cases and repeated antibiotic use.
Vulvovaginal Candidiasis Treatment Market: Segmentation
Valuable information covered in the FMI’s Vulvovaginal Candidiasis Treatment market report has been segregated into key segments and sub-segments.
Vulvovaginal Candidiasis Treatment Market by Drug Class:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
Vulvovaginal Candidiasis Treatment Market by Route of Administration:
- Oral Vulvovaginal Candidiasis Treatment
- Intravenous Vulvovaginal Candidiasis Treatment
- Topical Vulvovaginal Candidiasis Treatment
Vulvovaginal Candidiasis Treatment Market by Distribution Channel:
- Hospital Pharmacy for Vulvovaginal Candidiasis Treatment
- Retail Pharmacy for Vulvovaginal Candidiasis Treatment
- Online Pharmacy for Vulvovaginal Candidiasis Treatment
View More Details@ https://www.futuremarketinsights.com/reports/vulvovaginal-candidiasis-treatment-market
Key players covered in the report include:
- Astellas Pharma Inc.
- Mycovia Pharmaceuticals, Inc.
- Basilea Pharmaceutica Ltd.
- Scynexis, Inc.
- Grupo Ferrer Internacional S.A.
- Pfizer, Inc.
- Cadila Pharmaceuticals
- Bayer AG.
- Bristol-Myers Squibb Company
